On Tuesday, Juul Labs agreed to a $438.5 million settlement across multiple states, concluding a two-year bipartisan investigation into the e-cigarette manufacturer's marketing and sales practices that targeted youth.
In a statement, Juul stated that the settlement agreement is "an important component of our ongoing commitment to addressing past issues. Recently, we provided scientific and evidentiary proof to the US Food and Drug Administration that its marketing denial order (MDO) regarding our products was flawed both substantively and procedurally, and should be revoked.
According to the office of the Texas Attorney General, the agreement also includes marketing restrictions for individuals under the age of 35, limitations on in-store and online displays and sales, as well as age verification requirements for all sales.
Texas Attorney General Ken Paxton stated, "My commitment to protecting consumers from deceptive business practices is unwavering, and any company that misleads Texans, especially our young people, will be held accountable for their actions.
The state of Texas will receive $42.8 million from a settlement. The Attorney General's office stated that the $438.5 million settlement will be paid out over a period of 5 to 10 years, but if Juul chooses to extend the payment schedule to the maximum timeframe, the settlement amount could reach $476.6 million.
In late 2018, cigarette manufacturer Altria, maker of Marlboro, acquired a 35% stake in Juul for approximately $13 billion. As of July of this year, these shares were estimated to be valued at $4.5 billion.
This article contains excerpts or reprints sourced from third-party information, whose copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any unit or individual that needs to reprint must contact the author and should not directly reprint the content.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
